EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial

Patrick B Mark iD, Erika De Sousa-Amorim, Anna L Eriksson, Maria Leonsson-Zachrisson, Nicolas J Guzman, Matthew T Miller, Yunyun Jiang, Hiddo J L Heerspink iD

Nephrology Dialysis Transplantation · 26.11.2025 · 40 (12) · 2280-2288

DOI: 10.1093/ndt/gfaf119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.07.2025. Verfasst von Patrick B Mark und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Glucosides, Renal Insufficiency, Chronic, Benzhydryl Compounds, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis Despite benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) being recommended for treatment of chronic kidney disease (CKD), there is still an unmet need for managing renal residual risk. Based on pre-clinical data, balcinrenone is a novel mineralocorticoid receptor antagonist that maintains cardio-renal benefits without increasing hyperkalaemia risk. Use of balcinrenone and dapagliflozin is expected to provide complementary and additive kidney and cardiovascular protection. The MIRO-CKD study tests the hypothesis that balcinrenone with dapagliflozin is superior to dapagliflozin alone in reducing albuminuria in patients with CKD.

Methods

MIRO-CKD is a double-blind, active-controlled, phase 2b study evaluating the efficacy and safety of balcinrenone/dapagliflozin in 300 adults (planned) with CKD, estimated glomerular filtration rate (eGFR) 25–60 mL/min/1.73 m2 and serum potassium within normal range. Participants are being randomized 1:1:1 to balcinrenone/dapagliflozin 15 mg/10 mg, 40 mg/10 mg or placebo/dapagliflozin 10 mg for 12 weeks, followed by an 8-week wash-out period to assess off-drug effects. The primary endpoint is the change in log-transformed urinary albumin-to-creatinine ratio (UACR) from baseline to Week 12. Other outcomes include pharmacokinetics, safety and tolerability.

Results

A total of 614 patients were screened and 324 were randomized across 15 countries in Asia, Europe, and North and South America. There were 56.2% of participants taking SGLT2i and 87.1% renin–angiotensin–aldosterone system inhibitors at enrolment. The patient population are at increased risk of CKD progression by having CKD stage 3/4 and albuminuria (median UACR: 365.5 mg/g; mean eGFR: 42.2 mL/min/1.73 m2). 56.5% of participants had type 2 diabetes mellitus.

Conclusions

MIRO-CKD is a fully recruited global trial enrolling a contemporary CKD population at increased risk of progression and with an increased risk of hyperkalaemia based on their reduced kidney function. The study will assess the efficacy, safety and tolerability of the combination of balcinrenone and dapagliflozin to identify an optimal dose for a future phase 3 study in patients with CKD. Clinical Trial Registration Number NCT06350123.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesRenal Insufficiency, ChronicBenzhydryl CompoundsMineralocorticoid Receptor AntagonistsAlbuminuriaHumansDouble-Blind MethodGlomerular Filtration RateMaleFemaleMiddle AgedPrognosisSodium-Glucose Transporter 2 InhibitorsFollow-Up StudiesAgedAdultClinical Trials, Phase II as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicGlycosides

Stichwörter der Autor:innen

balcinrenonechronic kidney disease (CKD)dapagliflozinefficacysafety

Substanzen

GlucosidesdapagliflozinBenzhydryl Compounds(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triolMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsGlycosides

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
  • Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK.
  • Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
  • Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Late-stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Biometrics, Late Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.

ORCID-Profile: Patrick B Mark, Hiddo J L Heerspink

Förderung

  • AstraZeneca

Zitieren

APA

Mark, P. B., De Sousa-Amorim, E., Eriksson, A. L., Leonsson-Zachrisson, M., Guzman, N. J., Miller, M. T., Jiang, Y., & Heerspink, H. J. L. (2025). Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial. Nephrology Dialysis Transplantation, 40(12), 2280-2288. https://doi.org/10.1093/ndt/gfaf119

Vancouver

Mark PB, De Sousa-Amorim E, Eriksson AL, Leonsson-Zachrisson M, Guzman NJ, Miller MT, et al. Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial. Nephrology Dialysis Transplantation. 2025;40(12):2280-2288. doi:10.1093/ndt/gfaf119

BibTeX
@article{Mark2025,
  author = {Mark, Patrick B and De Sousa-Amorim, Erika and Eriksson, Anna L and Leonsson-Zachrisson, Maria and Guzman, Nicolas J and Miller, Matthew T and Jiang, Yunyun and Heerspink, Hiddo J L},
  title = {Efficacy and safety of balcinrenone and dapagliflozin for CKD: design and baseline characteristics of the MIRO-CKD trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {12},
  pages = {2280--2288},
  doi = {10.1093/ndt/gfaf119}
}
Kostenlos starten →